Prenuvo vs Ezra: Which Full-Body MRI Is Right for You?
Among the most-searched comparisons in preventive medicine in 2026: Prenuvo vs Ezra. Both providers operate in major US metros and offer similar core service (full-body MRI screening). The differences are in scan duration, sequence depth, AI augmentation, pricing tiers, and bundled add-ons.
At a Glance
| Dimension | Full-Body MRI Screening | Full-Body MRI Screening |
|---|---|---|
| Founded | 2018 (Vancouver) | 2018 (New York) |
| US locations (2026) | 12+ cities | 8+ cities |
| Base scan price | $2,499 | $1,495 |
| Enhanced/full scan price | Single price | $2,495 (full body) |
| Scan duration | 60 minutes | 30-45 min base / 60 min full |
| Body coverage | Head to ankles | Torso (base) / Head to thighs (full) |
| Scanner type | 3-Tesla MRI | 3-Tesla MRI |
| AI augmentation | AI-assisted; radiologist signs | Heavy AI emphasis; radiologist signs |
| Radiologist interpretation | Board-certified, in-house | Board-certified, mix of in-house and contracted |
| Follow-up consultation | Included (video review) | Included (video review) |
| Report turnaround | 5-10 business days | 5-10 business days |
| Bundled add-ons | Basic blood panel optional | Blood panel + DEXA + flow MRI optional add-ons |
| Notable marketing | Kim Kardashian (2024), Peter Attia podcast features | Tim Ferriss podcast features, broader health-tech positioning |
About this comparison
Prenuvo and Ezra are the two largest consumer full-body MRI providers in the United States. Both offer non-contrast 3-Tesla MRI screening for cancer and other conditions in asymptomatic adults. Prenuvo emphasizes a longer, more comprehensive scan protocol; Ezra offers tiered pricing with AI-augmented interpretation and a faster base scan. Q Bio and Neko Health are also entering the consumer scan market.
Patients who want the most comprehensive baseline body scan in a single session, who prefer Prenuvo locations (typically more US cities), and who value the longer scan protocol with broader body coverage. Worth the premium pricing for maximum coverage in one session.
Patients who want the lower-cost base scan ($1,495 vs $2,499), who value the modular tier approach (start with torso, add organs/regions later), and who want the heavier AI-augmented interpretation positioning. Ezra is more accessible for first-time consumer MRI patients on budget.
Cost comparison
Ezra base scan is $1,495 vs Prenuvo at $2,499 - a $1,000 difference at entry. Ezra full body matches Prenuvo at $2,495. Both providers run promotions; corporate wellness contracts can reduce per-scan pricing. Annual rescanning (recommended by Prenuvo) at $2,499/year is a significant ongoing commitment.
Evidence comparison
Both providers use 3-Tesla MRI with diffusion-weighted imaging sequences sensitive for cancer detection. Neither has published peer-reviewed outcome data comparing detection rates head-to-head. Both publish retrospective case examples but lack randomized trial evidence. The ACR (American College of Radiology) does not specifically endorse either; major medical societies remain skeptical of routine asymptomatic full-body MRI screening regardless of provider.
Frequently asked questions
Which is better, Prenuvo or Ezra? +
Neither is universally better. Prenuvo offers more comprehensive single-session scanning (60 minutes covering head-to-ankles, $2,499). Ezra offers a more affordable entry point ($1,495 base scan, torso-focused) with optional add-ons. For maximum baseline coverage in one session, Prenuvo. For lower-cost entry, Ezra.
Which is cheaper, Prenuvo or Ezra? +
Ezra base scan is the cheapest entry point at $1,495. Ezra full body matches Prenuvo at $2,495. Prenuvo only offers one comprehensive tier at $2,499. For limited budget, Ezra base; for maximum coverage, both providers are similarly priced at the full-body tier.
Which has more locations? +
Prenuvo has more US locations (12+ cities) versus Ezra (8+ cities) as of 2026. Both are expanding. Check current locations on each providers website.
Are the radiologists the same? +
Both providers use board-certified radiologists. Prenuvo employs in-house radiologists exclusively. Ezra uses a mix of in-house and contracted radiologists. Both providers AI-augment interpretation but maintain human radiologist sign-off.
Can I get insurance coverage for either? +
Neither is typically covered by insurance for routine asymptomatic screening. Both accept HSA/FSA payment. Some employer wellness programs include Prenuvo or Ezra as an executive benefit.
Which has better cancer detection rates? +
Neither has published peer-reviewed head-to-head detection rate data. Both providers publish anecdotal case examples. Routine asymptomatic screening with whole-body MRI detects clinically significant cancer in approximately 1-2 percent of patients regardless of provider.
Should I get scanned every year? +
Prenuvo recommends annual rescanning. Ezra is less prescriptive. No randomized trial evidence supports annual vs every 2-3 years vs single baseline for asymptomatic screening. Discuss with your personal physician based on family history and risk factors.
What about Q Bio and Neko Health? +
Q Bio offers a more comprehensive bundled package (MRI + bloodwork + biometrics) at $3,495. Neko Health, launched in Sweden and expanding to the US, offers a faster, lower-cost scan (~$299 in Sweden, US pricing pending). Both are competitive alternatives worth considering.
Bottom line
For most consumers in 2026: Ezra base scan at $1,495 is the most affordable entry to full-body MRI screening for chest, abdomen, pelvis. Prenuvo at $2,499 is the most comprehensive single-session option with head-to-ankle coverage. Both deliver board-certified radiologist interpretation and similar follow-up consultation. Choice depends on budget and whether comprehensive baseline (Prenuvo) or modular entry (Ezra) better fits your strategy.
Sources
- American College of Radiology. "ACR Statement on Whole-Body MRI Screening." 2023. (Position on routine asymptomatic screening)
- Hegenscheid K, et al. "Whole-body MRI in healthy volunteers." European Radiology, 2009. (Cancer detection rates in asymptomatic populations)